drugset / Trial / NCT05143229
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Phase 1
Active not recruiting
18 enrolled
University of Kansas Medical Center
Gilead Sciences · collabNovartis Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Timeline
- Start
- 2022-03-28
- Primary completion
- 2025-01-28
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 250 mg | Oral |
| Subject | Alpelisib | Small molecule | 300 mg | Oral |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |